Management of Bleeding with Newer Anticoagulants

Several novel oral anticoagulant drugs (NOACs) have recently been approved for use in patients with non-valvular atrial fibrillation or venous thromboembolic disease. These drugs are either direct thrombin inhibitors (dabigatran) or factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) and all have been compared in large randomized trials with warfarin. In general, NOACs are considered, at least, non-inferior to warfarin in terms of stroke prevention but their risk of bleeding is variable